Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Pulmonary Sarcoidosis
2013-005333-21Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing Canakinumab with Placebo (2 arms). Primary endpoint: Percentage change from baseline in forced vital capacity (FVC). Started Jan 2015; status: terminated.
02
Drugs
canakinumab
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on 2013-005333-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005333-21.